<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224428</url>
  </required_header>
  <id_info>
    <org_study_id>FEXT20</org_study_id>
    <nct_id>NCT04224428</nct_id>
  </id_info>
  <brief_title>Role of Fexofenadine in Diabetic Kidney Disease</brief_title>
  <official_title>Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  This study will that will be conducted on 60 outpatients previously diagnosed with type
           2 diabetes mellitus.

        -  Patients will be recruited from Internal Medicine Department, Tanta University Hospital,
           Tanta, Egypt.

      This study will be randomized, controlled, parallel, prospective clinical study. Accepted
      patients will be randomized into 2 groups as the following

        -  Group 1 (Control group): 30 patients will receive maximum tolerated dose of ACEI for six
           months

        -  Group 2 (Fexofenadine group): 30 patients will receive maximum tolerated dose of ACEI
           plus fexofenadine tablets 60 mg once daily for six months

      The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) after
      six months of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in urinary albumin creatinine ratio (UACR)</measure>
    <time_frame>After 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary cyclophilin A</measure>
    <time_frame>After 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary monocyte chemoattractant protein-1 (MCP-1)</measure>
    <time_frame>After 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine Pill</intervention_name>
    <description>fexofenadine tablets 60 mg once daily will be taken for six months</description>
    <arm_group_label>Fexofenadine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>lactose oral tablet</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged â‰¥ 18 years

          -  Confirmed diagnosis of Type 2 diabetes mellitus at least 6 months prior to screening

          -  Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary
             albumin creatinine ratio (UACR) &gt;30mg/g) despite treatment with maximum tolerated dose
             of ACE inhibitors for at least 8 weeks prior to the screening

          -  Hemoglobin A1c &gt; 6.5 % with regular use of insulin and/or oral glucose lowering agents

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Severe renal impairment (eGFR&lt; 30 mL/min/1.73 m2 at screening)

          -  Pregnant or lactating women

          -  Chronic heart failure

          -  Malignancy

          -  Inflammatory or autoimmune disease

          -  History of kidney disease other than diabetic nephropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Basma M El-fatatry, Master</last_name>
    <phone>201094114899</phone>
    <email>basma.mahrous.clinical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Tanta University</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Basma Mahrous El-Fatatry</investigator_full_name>
    <investigator_title>Principal investigator, Assistant lecturer of Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

